



Company Announcement no. 6/2009

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, March 25, 2009

## **LifeCycle Pharma Increases Share Capital by 150,813 Shares as a Consequence of the Exercise of Employee Warrants**

LifeCycle Pharma A/S (OMX: LCP) has decided to increase its share capital by nom. 150,813 shares as a consequence of the exercise of warrants. The increase is executed without any pre-emption rights for the existing shareholders of the company or others.

The shares are subscribed in cash as follows: (1) Nom. 27,760 shares are subscribed against payment of DKK 6,0634 per share of nom. DKK 1. (2) Nom. 123,053 shares are subscribed against payment of DKK 6,4782 per share of nom. DKK 1. Gross proceeds to the company are DKK 964,929. The increase corresponds to approx. 0,27 % of the company's share capital after the increase. The new shares are ordinary bearer shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the date of the registration of the capital increase with the Commerce and Companies Agency. The new shares will be listed on the NASDAQ OMX Copenhagen after registration with the said agency. The company's current share capital amounts to DKK 56,287,507 shares and will after the capital increase be DKK 56,438,320. The capital increase is expected to be finalized shortly.

### **For more information, please contact:**

LifeCycle Pharma A/S  
Peter Schøtt Knudsen  
Head of Investor Relations  
Phone: + 45 2055 3817  
Email: [PSK@lcpharma.com](mailto:PSK@lcpharma.com)

### **About LifeCycle Pharma A/S (LCP)**

*Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).*

*For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).*

LifeCycle Pharma A/S  
Kogle Allé 4  
DK-2970 Hørsholm  
CVR no. 26 52 77 67

Company Announcement no. 6/2009